The medication is commonly used to provide symptomatic relief in conditions involving inflammatory or irritative processes where symptoms related to physical discomfort and heightened physiological activity are present. This combined formulation is applied across domains where additional symptomatic support is needed to ease distressing manifestations. The key area of symptomatic focus involves supporting relief from the dual presence of persistent coughing and constricted airways, relevant in situations like acute bronchitis and post-infectious bronchial irritation.

Targeting the Persistent, Unproductive Cough

This component helps address the symptom cluster of an unproductive, dry cough that is often irritating and can interfere with daily functioning. The therapeutic benefit may be the moderation of the cough reflex, which supports the reduction of physical strain and contributes to easing the overall symptom load associated with persistent coughing.

Easing Restricted Airflow and Bronchial Tightness

In situations where patients experience both cough and symptoms linked to organ-specific functional stress due to airway constriction, Бронхотон is considered relevant for managing the symptoms of restricted airflow. Ingredients within this category, such as Ephedrine, are characterized by their historical use in managing mild symptoms like wheezing and chest tightness due to their action relevant for easing constricted airways. This action contributes to improved comfort by supporting easier breathing, which may assist with maintaining a sense of stability during acute episodes of bronchial irritation.

---

Therapeutic Relevance (Indications): The medication is relevant for managing persistent dry cough, symptoms of bronchial irritation, and restricted airflow associated with acute respiratory conditions.

Quick Fact: Relief for Dual Symptoms The formulation is commonly used when patients need support for both moderation of the cough reflex and easier breathing simultaneously.

“The combined approach may assist patients with coping more steadily during symptomatic periods by addressing distressing manifestations of both the cough reflex and physical airway discomfort.”

Regulatory References

1. NIH StatPearls - Ephedrine

The eligibility profile for Бронхотон, a combined antitussive and bronchodilator agent, is strictly defined by regulatory authorities based on the properties of its active components. The official criteria determine who may use the medicine and who must be excluded.

Category	Official Regulatory Statement
Populations for whom use is contraindicated	Individuals with known hypersensitivity to the active ingredients or excipients. Patients currently receiving non-selective Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of stopping MAOIs. Contraindicated in patients with severe coronary heart disease, hypertension, arrhythmias, and glaucoma.
Populations for whom use is not recommended	Use is generally not recommended for children under 12 years as official data regarding safety and efficacy are often insufficient or not established. Use is generally contraindicated or should be avoided during pregnancy and the lactation period.
Eligibility-related restrictions	Use with caution or great care is required for patients with diabetes mellitus, hyperthyroidism, prostatic hypertrophy, and renal impairment.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on pre-existing comorbidities and drug interactions. This framework mandates conditional use for patients with specific metabolic or organ function restrictions, and formally limits the population by restricting use in children under 12 and pregnant or breastfeeding women.

Interactions with other medicines and products

The interaction profile for Бронхотон is defined by the regulatory warnings associated with its active components, Ephedrine and Glaucine, and is structured around strict constraints for co-administration.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a prohibited combination. This severe pharmacodynamic interaction, stemming from the sympathomimetic action of Ephedrine, requires a mandatory timing separation. Regulatory documents specify a minimum 14-day washout period must elapse after discontinuation of an MAOI before this medicine can be administered.

Pharmacokinetic and Pharmacodynamic Interactions

The Glaucine component is susceptible to pharmacokinetic interaction involving metabolism. Inhibitors of the enzyme CYP2D6 are documented to reduce Glaucine clearance, officially resulting in increased Glaucine plasma concentrations.

The Ephedrine component has documented pharmacodynamic interactions with several classes. Co-administration with other sympathomimetic agents is subject to warnings due to additive cardiovascular and CNS stimulant effects. Similarly, Ephedrine may formally counteract the therapeutic effect of antihypertensive medicines. Official cautions also extend to the use of alcohol and other CNS depressants due to the risk of augmented central nervous system depression.

Бронхотон is a combination product whose pharmacodynamic effect is mediated by its two active components, glaucine hydrobromide and ephedrine hydrochloride. Glaucine acts on the central nervous system, functioning as a non-opioid agonist at the Sigma-1 receptor in the medulla oblongata's cough center. This agonist interaction modulates neural signaling pathways, resulting in a reduction of the afferent signal required to trigger the cough reflex. Ephedrine is an indirect-acting sympathomimetic amine. It primarily targets the peripheral sympathetic nervous system by promoting the release of endogenous norepinephrine from storage vesicles in postganglionic nerve terminals. Norepinephrine subsequently acts as an agonist at beta2-adrenergic receptors located on bronchial smooth muscle cells.

Activation of beta2-adrenergic receptors, which are G-protein coupled receptors, stimulates the intracellular enzyme adenylyl cyclase. This enzyme catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). The resultant increase in intracellular cAMP concentration activates Protein Kinase A (PKA). Active PKA phosphorylates target proteins, which leads to the inactivation of myosin light-chain kinase and subsequent relaxation of the bronchial smooth muscle. This cellular cascade results in the systemic physiological consequence of bronchodilation. Additionally, ephedrine's agonism at alpha-adrenergic receptors on the bronchial mucosa's vasculature induces vasoconstriction, which modulates fluid extravasation into the tissue.

The administration of Бронхотон syrup involves a standardized oral regimen for short-term symptomatic use. The treatment is designed as a fixed-course therapy, with the typical duration of use set between 5 and 7 days. Continuation of the regimen beyond this time frame requires review by a healthcare professional, as the specified period establishes the limit for unsupervised administration.

The administration method is oral use via the syrup formulation. Dosing is standardized based on the patient's age. For adults, the recommended unit dose is 15 ml (one tablespoon), taken as a divided regimen of three to four times daily.

Pediatric administration rules are distinct and scaled by age. Children between 3 and 10 years of age are designated a unit dose of 5 ml (one teaspoon) three times daily. Those over 10 years of age receive 10 ml (two teaspoons) three times daily. The product is not authorized for administration to children under 3 years of age.

The formulation's composition includes sucrose and ethanol, which is a condition of use relevant to the preparation's overall content. These factors are part of the procedural structure for consistent product use.

Бронхотон: Recent Clinical Evidence

---

Evidence for Use in Persistent, Unproductive Cough

Research exploring symptoms related to persistent cough focuses on the Glaucine component, which was evaluated in randomized, double-blind, crossover clinical trials. These studies are relevant in trials assessing short-term or episodic symptom patterns in adult populations affected by chronic cough. Researchers monitored the component's role by objectively measuring outcomes related to cough frequency over short observation periods, usually for several hours after a single dose. These findings describe patterns observed in the studies compared to placebo and established comparison treatments.

Evidence for Use in Acute Bronchial Irritation and Restricted Airflow

The study design for combination products in conditions associated with acute or disruptive episodes (such as acute bronchitis) typically involves randomized, placebo-controlled trials. This research model has explored whether studies examining similar fixed-dose combinations can monitor physiological strain or stress in adult outpatients. Outcomes assessed include tracking changes in symptom intensity over a course of treatment, such as utilizing the Bronchitis Severity Score (BSS).

Research Limitations and Uncertainty

The evidence is limited for the specific triple-component formulation. There is a critical absence of dedicated published randomized controlled trials that research examined the full combination of Glaucine, Ephedrine, and Ocimum Basilicum Oleum. Consequently, the certainty remains low for the formulation as a whole, and comparative evidence is lacking.

Follow-up durations were restricted to single-dose observation periods (up to 8 hours) or short-term treatment periods (7 to 10 days) in acute studies. The long-term effects are not fully established, and data for certain groups remain insufficient, including children, older adults, or populations related to pregnancy. The results apply only to the populations studied in the short term.

Key Studies & References

1. NIH StatPearls: Ephedrine Monograph and Sympathomimetic Amines

Common questions about Бронхотон (FAQ)

Q: What are the known interactions between Бронхотон and common over-the-counter pain relievers?

Official product information details interactions based on the drug's pharmacological properties, often listing interactions by specific drug classes such as sympathomimetics or CNS depressants. These documents may not specifically name every common over-the-counter (OTC) medicine. The official drug label's Interaction section should be consulted to determine if any ingredients in other medicines fall into a cautioned class.

Q: What is the recommended age range for the use of Бронхотон in children?

According to official regulatory guidance, documents establish a specific minimum age for administration and detail distinct dosing protocols for various pediatric age brackets. The limits established by official clinical data define the authorized administration boundaries for use. The guidelines specify that usage is generally not recommended for certain young age groups.

Q: Can Бронхотон be used by people who are sensitive to sulfites?

The official product information includes a complete list of all inactive ingredients, which are also known as excipients. This section contains the necessary details for individuals with known sensitivities to assess the contents before administration. This information helps to identify ingredients that may be associated with an allergic reaction.

Q: What is the list of inactive ingredients contained in the tablet formulation of Бронхотон?

Regulatory documents provide a full description of the composition for the official, marketed formulation(s). This includes the inactive ingredients, or excipients, used in the preparation. This information is available in the product description section of the official drug label for informational purposes.

Q: What kind of studies have been performed to examine the safety profile of Бронхотон?

The safety profile for the medicine is primarily established using data collected during the clinical trials that were required for regulatory approval. Official documents summarize this research, which typically includes pre-approval studies to monitor and assess adverse reactions related to its active components.

Q: Are there any specific foods that officially interact with Бронхотон?

Official regulatory labeling specifies whether there are any known clinically significant interactions between this medicine and specific foods. The drug's official instructions specify if consumption of any particular food is restricted during the course of treatment. This information is included to prevent altered drug effectiveness or adverse reactions.

Q: How long after starting Бронхотон can a patient typically expect to see improvement?

Official product information describes the medicine's pharmacological properties, which include the established onset of effect for the active components. This information provides an indication of the expected timeframe for the drug's therapeutic action to begin.

Q: What should be done if an adult forgets to take a dose of Бронхотон?

Official drug administration instructions include procedural guidance dedicated to managing forgotten or missed doses. This information is designed to help maintain the intended treatment regimen and avoid confusion about the timing of subsequent doses. The specific recommended steps for missed doses are detailed within the official dosage instructions.

Q: Does the efficacy of Бронхотон change when taken with food?

The administration instructions in the official drug label specify whether the medicine should be taken with or without food. This guidance is provided because food intake can sometimes alter the absorption of the active ingredients, which may impact the medicine’s overall effectiveness. The purpose of this guidance is to promote the medicine’s proper functioning.

Q: What are the official restrictions for using Бронхотон with pre-existing liver conditions?

Official regulatory documents include specific warnings and required precautions for use in use in patients with compromised organ function. This includes conditions related to hepatic, or liver, impairment. This is documented within official guidance.

Q: Is it true that Бронхотон can cause temporary changes in taste perception?

Official adverse reaction listings, which detail all reported side effects, include sensory disturbances. Temporary changes in taste perception (sometimes called dysgeusia) are documented in these official sources as a possible effect related to the medicine's use.

Q: Does Бронхотон require any special monitoring by a doctor during use?

Official patient instructions specify whether any routine patient monitoring is necessary during the course of treatment. This may include monitoring certain physiological metrics, like blood pressure, due to the presence of components like Ephedrine.

Q: What is the difference in action between Бронхотон and a pure expectorant?

Бронхотон is officially classified as a combined antitussive and bronchodilator agent, meaning it has a dual action: reducing the cough reflex and relaxing the airways. A pure expectorant, by contrast, has a distinct primary action focused solely on thinning mucus to make coughs more productive.

Q: What are the signs that a person should stop taking Бронхотон, based on official warnings?

Official safety warnings list serious adverse reactions that require immediate medical attention. These signs can include symptoms like severe chest pain, sudden changes in blood pressure, or unusual vision changes, which are noted in the Special Warnings section of the regulatory documents.

Q: Is it normal to feel a mild dry mouth while taking Бронхотон?

Dry mouth, or xerostomia, is listed among the potential adverse reactions detailed in the official drug label. It is a documented effect associated with the medication that occurs in some patients during the course of treatment.

Q: Do any official documents describe the potential for dependence with Бронхотон?

Regulatory documents, particularly those for medicines containing central nervous system-active components, typically include a dedicated section that addresses the potential for abuse, tolerance, and dependence. This information is legally mandated to inform patients and healthcare providers.

Storage Requirements

Official regulatory labeling dictates specific conditions necessary for storing Бронхотон syrup to maintain its stability. The product must be stored in a dry place, protected from light, and maintained within a controlled temperature range of 15 C to 25 C. This temperature range is essential for the product containing Ephedrine and Glaucine. The medicine must not be used after the expiration date printed on the packaging.

Child Safety and Handling

As a mandatory safety requirement, the medicine must be stored and kept out of the reach of children.

Disposal

Official instructions for disposal are not explicitly provided in the storage section of the labeling. Therefore, disposal of any unused or expired syrup must adhere to local pharmaceutical waste regulations and established guidelines for discarding medicines.